ZNF423 and breast carcinoma: Many breast cancer patients likely do not have functional BRCA1 mutations or abnormal BRCA1 CpG methylation, but since the MAF of the ZNF423 SNP is relatively high, the genotype for this SNP could be a useful factor in the selection of different treatments and could have potentially broad clinical implications.